

Amendments to the Claims

Claims 1-49 (Cancelled).

Claim 50 (Currently amended). An isolated tetrameric mammalian uricase, wherein said tetrameric uricase ~~is substantially free of~~ contains no more than about 10% non-tetrameric uricase aggregates.

Claim 51 (Previously presented). The isolated tetrameric uricase of Claim 50, wherein the uricase is porcine liver, bovine liver or ovine liver uricase.

Claim 52 (Previously presented). The isolated tetrameric uricase of Claim 50, wherein the uricase is recombinant.

Claim 53 (Currently amended). The isolated tetrameric uricase of Claim 52, wherein the uricase has ~~substantially~~ the sequence of porcine, bovine, ovine or baboon liver uricase.

Claim 54 (Previously presented). The isolated tetrameric uricase of Claim 52, wherein the uricase is chimeric.

Claim 55 (Previously presented). The isolated tetrameric uricase of Claim 54, wherein the chimeric uricase contains portions of porcine liver and baboon liver uricases.

Claim 56 (Previously presented). The isolated tetrameric uricase of Claim 55, wherein the chimeric uricase is pig-baboon chimeric uricase.

Claim 57 (Currently amended). The isolated tetrameric uricase of Claim 52, wherein the uricase is recombinant porcine uricase containing lysine in place of arginine at residue number 291 in SEQ ID NO:1 and serine in place of threonine at residue number 301 in SEQ ID NO:1.

Claim 58 (Currently amended). The isolated tetrameric uricase of Claim 52, wherein the uricase has ~~substantially~~ the sequence of baboon liver uricase in which tyrosine 97 in SEQ ID NO:2 has been replaced by histidine.

Claim 59 (Currently amended). The isolated tetrameric uricase of Claim 52, wherein the uricase comprises an amino terminal and a carboxyl terminal, and wherein the uricase is truncated at one terminal or both ~~terminals~~ termini.

Claims 60-73 (Cancelled).

Claim 74 (Previously presented). A pharmaceutical composition for lowering uric acid levels in a body fluid or tissue, comprising the isolated tetrameric uricase of Claim 50 and a pharmaceutically acceptable carrier.

Claim 75 (Previously presented). The pharmaceutical composition of claim 74, wherein said composition is stabilized by lyophilization and dissolves promptly upon reconstitution to provide solutions suitable for parenteral administration.

Claim 76 (Previously presented). The pharmaceutical composition of Claim 74, wherein said composition is stabilized by lyophilization and dissolves promptly upon reconstitution to provide solutions suitable for administration through inhalation.